DFRAI, By any chance have you been able to verify that article/report recently posted on SGXP over on Yahoo? Howard Liang is with Leerink Swann. Any idea if the poster on YH has been a reliable source of info? Thanks.
It wouldn't be surprising to see some C-met deals coming. I recently started nibbling on both SGXP and ARQL, and figure that even without an imminent deal, they're likely good long term holdings.
>>> ARQL-OP-bet you see a decent trade in the stock in the next few weeks. Howard Liang expects SGXP (not rated) to announce a partnership on their preclinical C-met inhibitor this summer. Hearing there are 10 term sheets out for SGXP drug and shaping up to possibly be the richest preclinical biotech deal ever. ARQL's ARQ-197(c-MET inhib entering ph 2-pancreatic cancer mid:07) is currently partnered only in Jap. Expect the SGXP deal to significantly raise awareness of c-MET class and could be 9 bidders walking away from bidding looking to license a c-MET. T =$12. <<<
News 
Market Data 
Discover 
